upadacitinib
upadacitinib: developed by 1 company · 26 clinical trials tracked · 2 FDA decisions.
upadacitinib evidence translation
What we can confirm
2 FDA records · 26 tracked trials
What it means
What to watch
Prepared research question
How could upadacitinib → ABBV affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Related indications
Development Pipeline (3)
| Company | Phase |
|---|---|
| AbbVie Inc. (ABBV) Atopic Dermatitis; Healthy Volunteer; Alopecia Areata | Phase 4 |
| AbbVie Inc. (ABBV) | Phase 4 |
| AbbVie Inc. (ABBV) | Phase 4 |
Clinical Trials (26)showing 10 most recent
Expanded Access to Upadacitinib
Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
Primary endpoint: Change in Disease Activity Score (DAS) 28
A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of Upadacitinib in Pediatric Subjects With Severe Alopecia Areata
Primary endpoint: Percentage of Participants with the Achievement of Severity of Alopecia Tool (SALT) Score <= 20, defined as less than or equal to 20% scalp hair loss.
Safety and Efficacy of Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations
Primary endpoint: Treatment Efficacy - TIme to first occurrence of disease reactivation
An Open-Label, Investigator-Initiated Study Evaluating the Use of Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis
Primary endpoint: Treatment Failure
A Phase 1 Study to Evaluate the Pharmacokinetic Interaction and Safety of ABBV-722 and Upadacitinib Following Multiple Oral Doses in Healthy Adult Subjects
Primary endpoint: Maximum observed plasma concentration at steady state (Cmax,ss) of ABBV-722
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Alopecia Areata and at Least 25% Scalp Hair Loss
Primary endpoint: Percentage of Participants with the Achievement of Severity of Alopecia Tool (SALT) Score <= 10
A Randomized, Double-Blind, Phase 3b Study to Evaluate the Short- and Long-Term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab and Oral Placebo for Induction Followed by Intravenous Vedolizumab Monotherapy for Maintenance in the Treatment of Adults With Moderately to Severely Active Crohn's Disease
Primary endpoint: Percentage of Participants Achieving Clinical Remission Based on the CDAI at Week 12
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis
Primary endpoint: Percentage of Participants Achieving Eczema Area and Severity Index (EASI) 75
A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Primary endpoint: Percentage of Participants Achieving a 75% Reduction from Baseline in Eczema Area and Severity Index 75 (EASI 75) Score (other than US)
FDA Decisions2 records
Frequently asked questions
Who is developing upadacitinib?
upadacitinib is being developed by AbbVie Inc..
How many clinical trials involve upadacitinib?
BioSniper tracks 26 clinical trials involving upadacitinib.
What is upadacitinib's latest FDA decision?
The most recent tracked FDA decision for upadacitinib is Approval, dated April 26, 2024.